



### Journal of Veterinary Practice and Health

# Mycobacterium caprae infection across species: A one health perspective on domestic animals, wildlife, and humans

Sara H. Mahrous<sup>1</sup>, Noha A.S. Saleh<sup>2,\*</sup>, Mohamed H. Hamad<sup>1,3</sup>

- <sup>1</sup> Infectious Diseases, Department of Animal Medicine, Faculty of Veterinary Medicine, Zagazig University, Zagazig 44511, Egypt
- <sup>2</sup> Department of Animal Wealth Development, Faculty of Veterinary Medicine, Zagazig University, Zagazig 44511, Egypt
- <sup>3</sup> Department of Animal Diseases, Faculty of Veterinary Medicine, King Salman International University, Ras Sudr 46612, Egypt Received: 11, 10, 2025; Accepted: 19, 11, 2025; Published: 17, 12, 2025
- © 2025 The Authors. Published by Science Park Publisher. This is an open access article under the CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/)

#### **Abstract**

Mycobacterium caprae (M. caprae), a member of the Mycobacterium tuberculosis complex (MTBC), is an emerging zoonotic pathogen of increasing concern in both veterinary and public health sectors. While traditionally associated with caprine tuberculosis, M. caprae has been reported in a wide range of domestic animals, wildlife species, and humans across Europe, Asia, and Africa. Its broad host range highlights the importance of adopting a One Health framework to understand and mitigate its transmission dynamics. In livestock, M. caprae infection leads to significant economic losses due to trade restrictions, decreased productivity, and the need for culling. Wildlife reservoirs, including deer, wild boar, and other ungulates, complicate eradication efforts and create persistent sources of infection. Human cases, often linked to zoonotic exposure through unpasteurized dairy products or direct animal contact, emphasize the public health risks associated with cross-species transmission. Despite its growing significance, M. caprae remains underdiagnosed and frequently misidentified as other MTBC members, limiting accurate surveillance and control. Limitations of conventional diagnostic methods and inconsistent use of molecular typing have contributed to underdiagnosis and misclassification, obscuring both burden and transmission pathways. This review synthesizes current knowledge on the pathogen's ecology, epidemiology, diagnostic challenges, and control implications from a One Health perspective. A coordinated One Health approach, integrating veterinary, medical, and ecological perspectives, is essential for the effective detection, prevention, and control of M. caprae infections globally.

**Keywords:** Tuberculosis, *Mycobacterium caprae*, Epidemiology, Wildlife, One Health, Molecular typing

### List of abbreviations

The following abbreviations are used in the review:

AMR Antimicrobial resistance

EU European Union
 IFN-γ Interferon-gamma
 LJ Lowenstein-Jensen
 M.caprae Mycobacterium caprae

MIRU-VNTR Mycobacterial Interspersed Repetitive Units-Variable Number

**Tandem Repeats** 

MTBC Mycobacterium tuberculosis complex OHCEA One Health Central and Eastern Africa

PZA Pyrazinamide

RD4 Region of Difference 4

SACIDS Southern African Centre for Infectious Disease SurveilLance

SNP Single Nucleotide Polymorphism

TB Tuberculosis

TST Tuberculin skin test

UVGI Ultraviolet germicidal irradiation

WGS Whole genome sequencing

### 1. Introduction

Tuberculosis (TB) remains one of the most serious infectious diseases worldwide, affecting both humans and animals. It is a chronic granulomatous disease characterized by long-term persistence, insidious progression, and the ability to cross species barriers [1]. Caused by members of the *Mycobacterium tuberculosis* complex (*MTBC*), the primary disease-causing species within this group include *M. tuberculosis*, *M. africanum*, *M. bovis*, and *M. caprae*.

M. caprae has emerged over the last two decades as an important multi-host pathogen that affects domestic livestock, a range of wild animals, and humans [2-4]. Historically considered a subspecies of M. bovis, M. caprae is genetically distinct and has been documented repeatedly. It causes bovinelike tuberculosis in goats and cattle and establishes infection reservoirs in wildlife such as wild boar and red deer [5-7]. From a One Health viewpoint, M. caprae exemplifies the interconnectedness of animal, human, and environmental health. Transmission occurs at multiple interfaces: between livestock (notably goats and cattle) via close contact and shared housing or pasture; between wildlife and livestock, where overlapping grazing or contaminated environments allow spillover and maintenance; and to humans, primarily through occupational exposures, direct contact with infected animals, or consumption of unpasteurized dairy products in areas where animal TB is not fully controlled. These multidirectional transmission pathways complicate control efforts and underline the need for integrated surveillance and intervention [3, 8-10].

Recent genomic and epidemiological studies have highlighted how animal trade, farm management practices, and wildlife ecology shape the regional distribution and persistence of M. caprae. One Health investigations in Europe have revealed long-term circulation of clonal lineages across livestock, wildlife, and occasionally humans, indicating both cryptic transmission chains and spillover events that standard livestock-only control programs can fail to capture (e.g., Bulgarian whole-genome sequencing phylogeography in cattle; Italy genotyping combining spoligotyping/ exact tandem repeat; occupational cases in Greece) [11-13]. Accurate detection and characterization of M. caprae are therefore essential but remain challenging. Conventional diagnostic tools used for bovine tuberculosis such as the tuberculin skin test (TST), culture, and post-mortem examination can indicate infection but usually lack specieslevel resolution. Molecular typing approaches are critical to distinguish M. caprae from other members of the M. tuberculosis complex, to trace epidemiological links, and to guide targeted control strategies (e.g. the Region of Difference 4 (RD4) variants study; comparative genomics of M. bovis and M. caprae) [14, 15]. However, current research on M. caprae is limited in scope: most studies are restricted to certain European countries, with little data from Africa, Asia, or Latin America where caprine and bovine TB remain endemic (Tunisia study; Peru case report) [16]. Moreover, diagnostic limitations in wildlife, under-reporting of zoonotic human cases, and frequent misclassification of isolates as M. bovis or M. tuberculosis contribute to major gaps in our understanding of the true global burden and epidemiology of M. caprae infections. For example, the European Union (EU) 2023

zoonoses report points out that TB cases of zoonotic origin are highly likely to have been underestimated because many member states do not routinely distinguish *M. bovis* and *M. caprae* from *M. tuberculosis* in human TB cases [17].

### 2. Characteristic traits of M. caprae

*M. caprae* is an acid-fast, non-motile, non-spore-forming rod that is normally 0.2–0.6 μm wide and 1.0–10 μm long. Some strains generate smooth colonies, while others form rough colonies. The color of the colonies can vary from white to orange or pink [18]. The actual structure of the *MTBC* is uncertain due to the various taxonomic and nomenclatural alterations that have occurred among its species [19].

The species now known as *M. caprae* was originally described as *M. tuberculosis subsp. caprae* due to its initial identification from goats that had spread TB lesions [20], subsequently renamed as *M. bovis subsp. caprae* in accordance with Rule 27(3) of the Bacteriological Code [21]. The name *M. bovis subsp. caprae* proposed by Niemann [22] is not valid, since the type strain was not placed in two publicly available service collections in different nations when it was published [23] and finally promoted to the rank of species as *M. caprae* comb. nov., sp. nov.

*M.caprae* (ca'prae.): The name comes from the Latin feminine genitive noun caprae, meaning "of the goat," referring to Capra, the host species from which the organism was first isolated. The description is identical to that provided for M. tuberculosis subsp. Caprae (Aranaz et al., 1999) [20]. Moreover, isolates exhibit a particular variant of the gyrB gene, where nucleotide 1311 is a G and nucleotide 1410 is a C. The type strain is gM-1<sup>T</sup> (=CIP 105776<sup>T</sup> =ATCC BAA-824<sup>T</sup>) and displays the phenotypic and genotypic features assigned to this taxon [24].

M. caprae exhibits a particular set of phenotypic, biochemical, genetic, and genomic traits [25]. Phenotypic traits of the caprine mycobacterial isolates are poor hydrolysis of Tween 80 after 10 days and sensitivity to pyrazinamide (PZA) [26]. Biochemical characteristics include a lack of niacin accumulation, absence of nitrate reduction, no growth on Lebek's medium, and the ability to grow in the presence of 2 mg/ml thiophen-2-carboxylic acid hydrazide [24].

### 3. Epidemiology

### 3.1. Host range susceptibility

M. caprae exhibits a broad host range, capable of infecting humans as well as domestic and wild animals across multiple regions, as summarized in Table 1 [27, 28]. M. caprae was first recognized as the predominant pathogen responsible for tuberculosis in goats [24], but it has also been reported in a variety of domestic and wild animal species and its role in wildlife in the epidemiology is increasingly recognized. Between 2003 and 2014. M. caprae was isolated from 55 animals in Portugal, including 29 goats, 21 cattle, 1 sheep, and 4 wild boars [29]. Phylogenetic studies suggest that the most recent common ancestor of M. caprae in goats dates back to approximately 100 years ago, with frequent host transitions between goats, wild boars, and humans, likely driven by mixed farming practices, extensive animal management, and close human-animal interaction [10]. Moreover, the pathogen has been identified in both sheep and goats, indicating direct interspecies transmission between these animals [30]. Notably, an outbreak of tuberculosis caused by *M. caprae* was reported in Croatia, where both children and cattle from a small dairy farm were found to be infected, and the bacterium was isolated from both hosts [31].

In addition to traditional livestock, *M. caprae* has also been isolated from less common hosts. In Spain, the first case of TB caused by *M. caprae* in a dromedary camel was reported [3], and in Slovenia, the bacterium was detected in two bison and one dromedary camel housed in a zoo [32]. In Italy, although *M. caprae* has been detected in only about 9% of cattle isolates, it has been rarely reported in red deer [33], and for the first time, the genotype SB0866 with Mycobacterial Interspersed Repetitive Units–Variable Number Tandem Repeats (MIRU-VNTR) profile 4,1,5,4,4,11,4,2,4,3,8,7 was isolated from an adult sow [34]. Additionally, the first reported instance of *M. caprae* infection in a domestic cat in the United Kingdom occurred in a castrated male Bengal breed [35].

In the Iberian Peninsula, the bacterium was isolated from a fox in an area where recent outbreaks had affected cattle and goat herds, indicating its spread among wild carnivores [9]. The bacterium has also been reported in red deer (Cervus elaphus) within Austria's western states of Tyrol and Vorarlberg. In 2008, the prevalence of *M. caprae* in red deer was found to be up to 23% [36, 37], and *M. caprae* subtype Lech-tal was identified in a red fox (Vulpes vulpes) shot by a hunter in 2018 in the western part of Austria [38]. Additionally, *M. caprae* 

has been isolated from wild boar and roe deer, though not from bison populations in the Bieszczady Mountains in Southeast Poland [39]. Another concerning occurrence was reported in the Bieszczady Mountains region in a wild boar (Sus scrofa) [40]. Importantly, research has shown that infected wild boars can sustain the circulation of *M. caprae* strains within their populations and potentially transmit the infection to domestic goats. *M. caprae* infection was reported in a captive Borneo elephant (Elephas maximus borneensis) imported directly from Borneo Island after being orphaned [41]. This interspecies transmission compromises the effectiveness of TB eradication campaigns in livestock and poses a significant public health risk [8].

M. caprae represents a significant public health concern due to its zoonotic potential and the likelihood of transmission between animals and humans. Spain, which reports the highest number of zoonotic tuberculosis cases in humans annually in the EU, also documented notable M. caprae activity between 2018 and 2022, underscoring its ongoing role in human and animal TB [42]. However, due to limitations in diagnostic methods for accurately identifying MTBC strains, the reported cases of M. caprae infection in humans likely underestimate the true extent of the issue. The first bacteriologically confirmed case of human infection with M. caprae in Poland was reported in November 2012, involving a 46-year-old male [43]. Relatively few known cases of autochthonous humans have been discovered outside of continental Europe [6]. Human illness caused by M. caprae has only been documented in a few number of cases, primarily from Turkey and Central and Southern European nations [44-46]. Additionally, it has been identified as a causative agent of tuberculosis in humans in both Peru and northern Algeria, highlighting the critical need for species-level identification of MTBC members to ensure effective management and treatment of zoonotic TB [47, 48]

### 3.2. Patterns of infection spread among hosts

The main pathways for *M. caprae* infection are the consumption of unpasteurized dairy products and direct contact with infected animals. Reported cases involved 13 occupational exposures (seven goat farm workers, three cattle farm workers, two slaughterhouse workers, and one individual handling animal remains for fodder production), two family members of cattle owners, and five migrants from regions

where unpasteurized milk consumption is common (four from the Sahel region and one from Sub-Saharan Africa, with one specifically reporting the consumption of unpasteurized milk) [49]. Pigs typically become infected through the ingestion of unpasteurized milk or dairy by-products from infected cows, as well as unsterilized slaughterhouse waste. An incident reported on a family farm in the Czech Republic confirmed the transmission of *M. caprae* to domestic pigs through the consumption of contaminated cow's milk [50].

The detection of similar M. caprae genotypes in both red deer and cattle suggests that domestic cattle may have become infected over time through contact with free-ranging red deer, which have attained the position of maintenance hosts [51, 52]. Notably, M. caprae can be excreted in the feces of naturally infected red deer, indicating that red deer can play a role in the transmission and spread of the disease [53]. Cattle may contract the infection when the environment near to feeding areas is contaminated by excretions from infected wildlife, such as feces, urine, pus, or sputum. Extended crowding of red deer at feeding areas creates ideal conditions for close contact between individuals, increasing the risk of intraspecies transmission [36, 51, 52]. Another possible source of infection could be wildlife winter feeding locations, when contaminated food and salt licks are accessible. The likelihood of disease transmission between wildlife and domestic animals is influenced by several factors, such as species-specific behavior, herd management practices, and the virulence of the pathogen. A key contributor to transmission risk is the environmental persistence of mycobacteria, which can remain viable in soil and bedding materials for extended periods, even lasting several years [54, 55]. In Andalusia, the regions with the highest density of goat farms corresponded closely with the geographic distribution of human cases. Human M. caprae isolates were recovered from five Andalusian hospitals that routinely performed species-level identification of members of the M. tuberculosis complex. Most cases were associated with direct or indirect contact with livestock, particularly goats and cattle, or with individuals originating from countries where consumption of unpasteurized dairy products is common. In the majority of patients, tuberculosis involved the respiratory tract, indicating that airborne transmission from infected animals (via inhalation of aerosolized bacilli during close contact or handling of livestock) was the predominant route of

infection, while ingestion of contaminated milk or dairy products represented a secondary but possible transmission pathway [31, 49].

### 4. Insights into the pathogenesis and virulence mechanisms of *M. caprae*

M. caprae causes tuberculosis primarily in goats, sheep and other ruminants, but can spill over to cattle, wildlife, and humans [56]. Its pathogenesis follows the general MTBC paradigm: after inhalation or ingestion, bacilli are phagocytosed by macrophages, where they resist killing and establish infection, forming granulomas which may later caseate. Although M. caprae does not appear to carry unique classical toxins, comparative genomics has revealed several virulence-associated features shared with M. bovis and M. tuberculosis [57]. Key among these are conserved type VII secretion (ESX) systems, especially ESX-1 and ESX-5, which are involved in secretion of proteins like ESAT-6/CFP-10 that mediate phagosomal escape, modulation of immune responses, and virulence [58, 59]. Also, the lipid metabolism / stress-response gene families (e.g. those linked to mycolic acids, cell envelope lipids) are highly conserved and likely crucial for persistent infection and resistance to host defenses [58, 60]. Another locus of interest is the RD4, which is present in M. caprae (in many, but shows heterogeneity among isolates) but absent in M. bovis; this region appears to include genes involved in trehalose-containing glycolipid synthesis, which may affect virulence by influencing the cell envelope's properties and immune evasion [61]. Mutations or deletions in certain antigenic proteins, variation in host T-cell epitopes, and differences in peptidoglycan assembly also correlate with the variation in lesion severity, host range, and transmissibility among M. caprae isolates [57, 62]. Altogether, M. caprae's virulence arises not from novel toxins but from the capacity to modulate the immune response, survive in hostile intracellular environments, and adapt its envelope and secreted antigen repertoire to different hosts.

M. caprae infection in humans presents as pulmonary tuberculosis in most cases [43], but extrapulmonary forms, such as tuberculous meningitis, which is the most serious form of extrapulmonary tuberculosis, are relatively more *ulosis* infections. M. caprae causes tuberculosis in both animals and

humans via similar intracellular survival and immunemodulating mechanisms.

However, in humans, it tends to show different tissue preferences, reflecting partial host adaptation and genomic divergence from *M. bovis* and *M. tuberculosis* [46, 63-65].

### 5. Comprehensive diagnostic approaches for the detection of *M. caprae*

Diagnostic approaches for *M. caprae* rely on a combination of clinical evaluation, post-mortem examination, and laboratory testing [66].

### 5.1. Clinical and pathological features across species

M. caprae infection exhibits a wide clinical and pathological spectrum depending on the host species, route of infection, and disease stage, but it generally reflects the chronic and granulomatous nature of the disease. In domestic cats, infection may present as systemic illness with respiratory involvement, pyogranulomatous bronchopneumonia, and renal lesions, with histopathology revealing necrotizing granulomas containing moderate numbers of acid-fast bacilli in lymph nodes; infection often occurs via the respiratory tract, with hematogenous dissemination to other organs [35, 67]. In domestic ruminants such as cattle and goats, infection typically presents as a chronic, progressive condition, and many cases remain subclinical for long periods, with lesions often detected only at slaughter or postmortem examination [67]. Experimentally infected goats were euthanized and developed extensive tuberculous lesions in the lungs and respiratory lymph nodes [68]. while naturally infected cattle in endemic regions may exhibit lesions in the lungs, liver, intestines, and regional lymph nodes following alimentary or aerosol exposure, with histology showing sparse acid-fast bacilli but strong immunohistochemical positivity for mycobacterial antigens [69]. In camels, the disease manifests with progressive weight loss, dull coat, and lethargy, typically noted within two weeks prior to euthanasia. Necropsy findings include ascites, hydrothorax, and hydropericardium, along with numerous nodules measuring 0.5-3 cm in diameter scattered throughout the spleen and liver. Marked generalized lymph node enlargement is evident, particularly in the mesenteric and mediastinal nodes. The distribution of these gross lesions reflects systemic involvement [3].

In wildlife reservoirs, lesion patterns vary by species. In red foxes, disseminated disease may result in severe emaciation, blindness, depression, markedly enlarged lymph nodes with caseous necrosis, thickened pericardium with purulent exudate, discrete pulmonary granulomas, and multifocal caseopurulent renal necrosis [9]. In red deer, lesions are most

often located in the head lymph nodes, especially the medial retropharyngeal nodes, reflecting oral exposure; severity ranges from small granulomas to coalescing abscesses and generalized tuberculosis with lesions up to 200 mm in diameter [70].

Table 1. Comparative overview of M. caprae cases across regions and hosts.

Region	<b>Host Species Reported</b>	Critical considerations	References
Southern Europe (Spain, Italy, Portugal)	Goats, cattle, sheep, dromedary camel, domestic sow, wildlife	Spain reports the largest number of documented zoonotic TB (M. caprae) in humans within the EU.  In Portugal, isolates recovered between 2003 and 2014 demonstrated infection across multiple species, highlighting a broad host involvement.  In Italy, the genotype SB0866 of M. caprae was first detected in an adult sow.	[3, 29, 33]
Central Europe (Austria's western states of Tyrol and Vorarlberg, Slovenia)	Red deer, red fox, bison, dromedary camel	In Austria, red deer exhibited a high prevalence of <i>M. caprae</i> (up to 23%), and the Lech-tal subtype of the bacterium was additionally identified in a red fox, highlighting its circulation in both wild cervids and carnivores.  In Slovenia In Slovenia, cases of <i>M. caprae</i> were identified in zoo animals, including two bison and one dromedary camel.	[32, 36, 38, 39]
Western Europe (Croatia, United Kingdom)	Cattle, goats, domestic cat  Sporadic human cases	In Croatia, human cases are uncommon but have been occasionally reported, with some outbreaks traceable to livestock exposure.  In the United Kingdom, the first confirmed <i>M. caprae</i> case occurred in a cat.	[31, 35]
Southwest corner of Europe (Iberian Peninsula)	Goats, wild boars, foxes, humans	Host transitions occur between livestock, wildlife, and humans.	[9, 10]
Poland (Bieszczady Mountains)	Wild boar, roe deer, humans; not detected in bison	No cases have been detected in bison.	[39, 40, 43]
Czech Republic	Cattle, pigs	Transmission of <i>M. caprae</i> to domestic pigs can occur via consumption of cow's milk contaminated with the pathogen.	[50]
Asia (Borneo)	Borneo elephant (captive)	Documented infection in a captive Borneo elephant.	[41]
Turkey	Humans	Relatively few human cases have been identified.	[44-46]
Latin America (Peru)	Humans	M. caprae has been identified as a causative agent of human TB, emphasizing the importance of species-level identification within the MTBC.	[47]
Africa (Northern Algeria)	Cattle, humans	M. caprae has been observed in humans as a zoonotic pathogen transmitted from cattle to humans.	[48]

Wild boar commonly develop yellowish tubercles (1–5 mm) in submandibular, mediastinal, and tracheobronchial lymph nodes [39]. M. caprae was also recovered from the sputum of an elephant presenting with low-grade fever (99.9 °F), loss of appetite, progressive weight loss, and a productive cough [41]. In humans, M. caprae does not exhibit distinctive clinical manifestations, which can make it difficult to recognize as the causative agent of tuberculosis. These clinical manifestations are indistinguishable from those of M. tuberculosis. Pulmonary forms are most common, with chronic cough, fever, night sweats, and weight loss [49], while extrapulmonary involvement may include lymphadenitis, peritoneal TB, skeletal TB, genitourinary TB, and Tuberculous meningitis is the most serious form of extrapulmonary tuberculosis in children, especially infants [44, 65]. As in animals, gross pathology in human cases reveals caseous necrotizing granulomas, and histopathology shows classic tuberculous architecture with central necrosis and epithelioid cell layers, though definitive species identification requires microbiological culture and molecular typing [64, 71].

### 5.2. Conventional and molecular methods for laboratory diagnosis

The laboratory diagnosis of *M. caprae* in animals and humans involves a combination of ancillary, immunological, and molecular methods to ensure accurate detection and differentiation within the *MTBC*, as summarized in Table 2 [72].

Screening for MTBC infection typically begins with the TST, which serves as the primary diagnostic tool to detect cell-mediated immune responses to mycobacterial antigens. However, the sensitivity of the TST may be limited under certain conditions, such as early stages of infection, immunosuppression, or exposure to environmental mycobacteria. The interferon-gamma (IFN- $\gamma$ ) assay is generally regarded as more sensitive than the TST, providing an earlier and more reliable indication of infection. Nonetheless, both assays are unable to distinguish M. caprae from other members of the MTBC [73, 74].

*M. caprae* is a slow-growing, non-motile, acid-fast bacillus. On Lowenstein–Jensen (LJ) or Middlebrook 7H10/7H11 media, colonies of *M. caprae* generally appear rough, dry, and

cream to buff-colored, resembling those of *M. bovis*. Growth typically occurs after 3 to 8 weeks of incubation at 37 °C, and unlike *M. bovis*, *M. caprae* can also grow, though weakly, at 42 °C. Microscopically, the organism appears as slender, slightly curved rods, which stain red with Ziehl–Neelsen due to the high mycolic acid content in their cell wall [75-77]. Biochemically, *M. caprae* is niacin-negative, nitrate-negative, pyrazinamidase-positive, and catalase-negative at 68 °C, features that help distinguish it from *M. tuberculosis* and *M. bovis*. It is also susceptible to pyrazinamide, in contrast to *M. bovis*, which shows natural resistance to this drug [44, 78]. These biochemical and growth traits, in combination with molecular analyses such as spoligotyping or region of difference (RD) typing, are essential for accurate identification and differentiation of *M. caprae* within the *MTBC*.

In both animals and humans, molecular detection of MTBC from clinical specimens or culture isolates using real-time PCR provides a rapid and highly sensitive diagnostic approach. Targets such as IS6110 and IS1081, which are multicopy insertion sequences, enable efficient detection of MTBC DNA, even in samples with low bacterial load. The gyrB gene, encoding the DNA gyrase subunit B, contains sequence polymorphisms that allow for reliable species differentiation within the MTBC, including M. caprae, M. bovis, and M. tuberculosis. Similarly, amplification of the mpb64 gene, which encodes an immunogenic protein specific to MTBC species but absent in BCG strains, serves as an additional confirmatory marker for active infection. The combination of these genetic targets in multiplex or real-time PCR assays enhances diagnostic specificity and enables rapid species-level identification, supporting both clinical diagnosis and epidemiological tracing [64, 79-82].

Genotyping methods such as spoligotyping, IS6110-RFLP, and MIRU-VNTR are essential for epidemiological tracing, with MIRU-VNTR providing higher discriminatory power than spoligotyping. To distinguish *M. caprae* from other *MTBC* members, [83] discovered an additional *M.caprae*-specific single nucleotide polymorphism (SNP) at position 690 bp of the lepA gene. Genetic fingerprinting identifies unique characteristics of caprine mycobacterial isolates. By using first-generation membranes and direct variable repeat-spoligotyping, as described by [84], they constructed a homogeneous cluster that is clearly identified by the lack of

spacers 1, 3-16, 30-33, and 39-43. Additionally, caprine mycobacterial isolates are separated from M. bovis isolates by RFLP typing linked to IS6110, polymorphic GC-rich sequences, and direct repetitions [85, 86]. At the genomic level, it was first demonstrated that MTC species differed based on whether or not they have regions of differentiation (RD). RD9, RD7, RD8, RD10, RD5, RD6, RD12, RD13, and N-RD25 are absent from caprine isolates [87, 88]. Although a standardized panel of loci has not yet been established due to variations in allelic diversity among strains, MIRU-VNTR has shown high discriminatory power for M. caprae, enabling differentiation between closely related isolates and tracing transmission routes. Among the most informative loci for M. caprae differentiation are VNTR3232, QUB11a, ETR-B, and ETR-A, which provide strong resolution for epidemiological investigations [89].

### 6. Control and prevention of *M. caprae*: A one health perspective

The control and prevention of *M. caprae* infection require an integrated One Health approach combining veterinary, environmental, and human health strategies. As a zoonotic member of the *MTBC*, *M. caprae* can be transmitted directly between animals and humans or indirectly via contaminated environments, food products, or shared resources [90]. Routine surveillance of livestock, particularly goats and sheep, is essential for early detection and interruption of transmission chains. Veterinary programs should incorporate tuberculin skin testing, interferon-γ release assays, bacteriological culture, and molecular tools such as whole-genome sequencing (WGS) to differentiate *M. caprae* from other *MTBC* members [91].

Table 2. Summary of diagnostic approaches for M. caprae.

Diagnostic category	Key information	
General diagnostic approach	Diagnosis in animals and humans relies on ancillary tests, immunological assays,	
	culture, and molecular methods.	
TST	Primary screening tool for MTBC infection.	
IFN-γ	More sensitive than TST; offers an earlier indication of infection. Still unable to	
	differentiate M. caprae from other MTBC members.	
Culture characteristics	Slow-growing, non-motile, acid-fast bacilli. Rough, dry, cream to buff-colored	
	colonies on LJ or Middlebrook media. Growth in 3–8 weeks at 37 °C. Unlike M. bovis,	
	M. caprae can also grow, though weakly, at 42 °C.	
Microscopic features	Slender, slightly curved, acid-fast rods stained by Ziehl-Neelsen due to high mycolic	
	acid content.	
<b>Biochemical tests</b>	M. caprae is niacin-negative, nitrate-negative, pyrazinamidase-positive, and catalase-	
	negative.	
Molecular detection	Real-time PCR targeting IS6110 and IS1081 enables rapid and sensitive MTBC	
	detection. mpb64 gene amplification confirms MTBC infection; gyrB polymorphisms	
	allow species differentiation among <i>M. caprae</i> , <i>M. bovis</i> , and <i>M. tuberculosis</i> .	
Genotyping methods	Spoligotyping, IS6110-RFLP, and MIRU-VNTR are used for epidemiological studies;	
	MIRU-VNTR offers the highest discriminatory power.	
Species-specific markers	An M. caprae-specific SNP is identified at position 690 bp of the lepA gene.	
Spoligotype pattern	Characterized by the absence of spacers 1, 3–16, 30–33, and 39–43, forming a distinct	
	cluster.	
Differentiation from M. bovis	Achieved through IS6110-RFLP, polymorphic GC-rich sequences (PGRS), direct	
	repeat analysis, and specific RD deletions.	
MIRU-VNTR for M. caprae	Reliable for genotyping MTBC, including M. bovis and M. caprae. No universal locus	
	panel exists due to allelic diversity. Highly discriminatory for <i>M. caprae</i> ; informative	
	loci include VNTR3232, QUB11a, ETR-B, and ETR-A, which are useful for tracing	
	transmission chains.	

In humans, clinical suspicion should be raised in tuberculosis cases with a history of occupational animal contact or consumption of unpasteurized dairy products, and laboratory capacity for subspecies identification should be strengthened. Environmental contamination is a critical vet often underestimated factor in the epidemiology of M. caprae infections. Farms and grazing areas where domestic livestock interact with wildlife species such as badgers, wild boars, and deer pose a high transmission risk due to the shedding of infectious bacilli in feces, nasal secretions, and saliva [92]. The pathogen can persist for extended periods in soil, water, and organic matter while maintaining infectivity [93], enabling sustained transmission among livestock and wildlife. Breaking this environmental transmission cycle requires rigorous sanitation and disinfection measures targeting contaminated reservoirs. Effective strategies alternating the use of ethyl alcohol, sodium hypochlorite, and 20% lime milk for cleaning animal housing, equipment, and transport vehicles [94]. Weekly treatments of barns and exercise areas with 2% sodium hydroxide or quicklime help reduce microbial load. Monthly disinfection of sewage systems and cesspits using bleaching powder further limits persistence. The installation of permanent disinfection stations at farm entry and exit points, with bimonthly replenishment, enhances biosecurity [95].

In confined settings such as veterinary clinics, hospitals, and prisons, airborne transmission risk can be reduced through natural ventilation, with upper-room ultraviolet germicidal irradiation (UVGI) serving as a supplementary measure in poorly ventilated environments [96]. Incorporating these environmental control measures alongside regular monitoring is essential for mitigating the persistence and spread of *M. caprae* in agricultural and communal environments.

From an animal health perspective, test-and-slaughter or test-and-segregate policies remain central to removing infected livestock, alongside biosecurity measures that restrict herd mixing, regulate animal movement, and prevent wildlife access to feed and water sources through interventions such as raised troughs and anti-badger fencing [97]. While complete eradication of *MTBC* from wildlife is generally unfeasible, vaccination campaigns, such as BCG immunization of badgers in the United Kingdom, have shown potential in reducing bacterial shedding [98]. Several studies have demonstrated the

efficacy of BCG vaccination in reducing tuberculosis caused by *M. caprae* in animal models. In goats naturally exposed to *M. caprae*, a field trial showed that BCG vaccination lowered the prevalence of tuberculous lesions, with efficacy ranging from 53% to 75% depending on lesion location, indicating reduced disease severity and bacterial spread [99]. Similarly, in wild badgers, BCG vaccination not only reduced the risk of disease in vaccinated individuals but also provided indirect protection to unvaccinated cubs when a substantial proportion of their social group was immunized [100]. These results align with findings from wildlife and livestock tuberculosis control programs where BCG vaccination helped reduce bacterial shedding and transmission risk, supporting its use as a valuable tool in integrated control strategies against *MTBC* in animals.

Food safety is a critical element of prevention, as unpasteurized dairy products are a well-documented vehicle for zoonotic TB, including *M. caprae* [101]. Mandatory milk pasteurization, as implemented in Canada since 1991, has markedly reduced the risk of foodborne *MTBC* transmission [102]. Hygiene protocols for milking equipment, birthing areas, and personnel should be enforced to prevent contamination, while ensuring disinfectant residues do not enter the milk supply [103].

Public health control measures should prioritize targeted screening of high-risk occupational groups and travelers from endemic regions. Although human M. caprae infections are rare, a Canadian case in an elderly immigrant from Ukraine with a history of animal farming, reported by Riopel [104], demonstrates its zoonotic potential. The patient developed pulmonary tuberculosis, the isolate was fully susceptible to first-line drugs, and no secondary cases occurred, yet the outcome was fatal. Such cases, typically acquired abroad, highlight the importance of screening protocols that incorporate travel and occupational histories, support subspecies-level MTBC identification, and include diagnostic approaches for both pulmonary and extrapulmonary disease. The WHO-OIE-FAO Roadmap for Zoonotic Tuberculosis aims to reduce TB mortality by 95% and incidence by 90% by 2035, but persistent environmental reservoirs and crossspecies transmission remain significant barriers [105]. Special attention should be given to vulnerable populations, including those with HIV infection, for whom environmental exposure

can accelerate disease progression and complicate treatment [106]. Progress toward these targets will depend on sustained coordination between veterinary and human health sectors, enhanced environmental surveillance, public awareness campaigns, and the application of molecular epidemiology to identify and interrupt transmission routes.

## 7. Future directions for surveillance of *M. caprae*

Future research on M. caprae infection should prioritize genomic surveillance to enhance the detection of transmission clusters, trace cross-species spillover events, and monitor the emergence of drug-resistant strains, building on established whole-genome sequencing (WGS) frameworks for zoonotic tuberculosis. Robust surveillance systems are essential for identifying emerging disease threats and antimicrobial resistance (AMR), guiding treatment and mitigation strategies, evaluating the effectiveness of current control measures, and informing evidence-based policy and regulation. These systems typically operate at national or subnational levels and monitor infections and AMR in animals, farm workers, the general human population, and at the interfaces linking livestock, humans, wildlife, and the environment [13, 107]. Strengthening interdisciplinary One Health collaborations including veterinarians. medical professionals, microbiologists, epidemiologists, and wildlife ecologists is vital for early detection, coordinated outbreak response, and the development of effective control policies for zoonotic tuberculosis [108]. Experiences from initiatives such as the Southern African Centre for Infectious Disease Surveillance (SACIDS), One Health Central and Eastern Africa (OHCEA), and AfriqueOne in Tanzania demonstrate how multisectoral partnerships can enhance infectious disease surveillance, including for mycobacterial infections. Therefore, advancing the One Health approach through strong intersectoral collaboration among stakeholders, governmental sectors, and communities is essential to address the complex factors shaping the health and well-being of humans, animals, and ecosystems [109].

#### 8. Conclusion

*M. caprae* is emerging as a notable pathogen within the interconnected One Health framework of humans, animals, and the environment. Its persistence in multi-host systems

demonstrates that eradication strategies focusing solely on livestock are insufficient. Wildlife reservoirs and ecological factors must be considered in long-term control policies. Advances in molecular epidemiology, including wholegenome sequencing, offer promising tools to improve surveillance and trace transmission pathways. However, their routine application remains limited in many regions. Building stronger links between veterinary, medical, and environmental sectors will be critical to closing diagnostic and epidemiological gaps. Ultimately, controlling *M. caprae* requires moving beyond traditional species-specific frameworks toward a truly integrated One Health strategy.

### **Author contributions**

The authors conducted the research and data analysis, and were responsible for writing and approving the review. All authors have thoroughly reviewed the work and provided their consent to the final version.

#### **Conflicts of interest**

All authors declare no conflicts of interest.

### **Funding statement**

This manuscript received no external funding.

### **Disclaimer**

Sara H. Mahrous, as an Editorial Officer of this journal, didn't participate in the peer review, editorial handling, or decision making of this manuscript. Full responsibility for the editorial process was under the Editor-in-Chief's supervision.

### **Author information**

Corresponding Author: Noha A.S. Saleh \*

**E-mail:** nohaatef054@gmail.com **ORCID iD:** 0009-0008-8270-2941

### **Data availability**

Data will be available on request.

### References

[1] Brites, D., Loiseau, C., Menardo, F., Borrell, S., Boniotti, M. B., Warren, R., ... & Gagneux, S. (2018). A new phylogenetic framework for the animal-adapted Mycobacterium tuberculosis complex. Frontiers in Microbiology, 9, 1-14. <a href="https://doi.org/10.3389/fmicb.2018.02820">https://doi.org/10.3389/fmicb.2018.02820</a>

- [2] Asmare, K., Sibhat, B., Demissie, K., Mamo, G., Skjerve, E., & Ameni, G. (2020). Tuberculosis in small ruminants and dromedary camels in Ethiopia: A systematic review and meta-analysis. Preventive Veterinary Medicine, 185, 105181. https://doi.org/10.1016/j.prevetmed.2020.105181
- [3] Infantes-Lorenzo, J. A., Romero, B., Rodríguez-Bertos, A., Roy, A., Ortega, J., de Juan, L., ... & Bezos, J. (2020). Tuberculosis caused by Mycobacterium caprae in a camel (Camelus dromedarius). BMC Veterinary Research, 16(1), 435. https://doi.org/10.1186/s12917-020-02665-0
- [4] Agyeman, A. A., & Ofori-Asenso, R. (2017). Tuberculosis—an overview. Journal of Public Health and Emergency, 1(1). https://doi.org/10.21037/jphe.2016.12.08
- [5] Prodinger, W. M., Eigentler, A., Allerberger, F., Schönbauer, M., & Glawischnig, W. (2002). Infection of red deer, cattle, and humans with *Mycobacterium bovis subsp. caprae* in western Austria. Journal of Clinical Microbiology, 40(6), 2270-2272. <a href="https://doi.org/10.1128/JCM">https://doi.org/10.1128/JCM</a> .40.6.2270-2272.2002
- [6] Prodinger, W. M., Brandstätter, A., Naumann, L., Pacciarini, M., Kubica, T., Boschiroli, M. L., ... & Moser, I. (2005). Characterization of *Mycobacterium caprae* isolates from Europe by mycobacterial interspersed repetitive unit genotyping. Journal of Clinical Microbiology, 43(10), 4984-4992. https://doi.org/10.1128/JCM.43.10.4984-4992.2005
- [7] Krajewska-Wędzina, M., Kozińska, M., Orłowska, B., Weiner, M., Szulowski, K., Augustynowicz-Kopeć, E., ... & Smith, N. H. (2018). Molecular characterisation of *Mycobacterium caprae* strains isolated in Poland. Veterinary Record, 182(10), 292. <a href="https://doi.org/10.1136/vr.104363">https://doi.org/10.1136/vr.104363</a>
- [8] Ciaravino, G., Vidal, E., Cortey, M., Martín, M., Sanz, A., Mercader, I., ... & Pérez de Val, B. (2021). Phylogenetic relationships investigation of *Mycobacterium caprae* strains from sympatric wild boar and goats based on whole genome sequencing. Transboundary and Emerging Diseases, 68(3), 1476-1486. <a href="https://doi.org/10.1111/tbed.13816">https://doi.org/10.1111/tbed.13816</a>
- [9] Pérez de Val, B., Perea, C., Estruch, J., Solano-Manrique, C., Riera, C., Sanz, A., ... & Velarde, R. (2022). Generalized tuberculosis due to *Mycobacterium caprae* in a red fox phylogenetically related to livestock breakdowns. BMC Veterinary Research, 18(1), 352. https://doi.org/10.1186/s12917-022-03454-7

- [10] Pereira, A. C., de Val, B. P., & Cunha, M. V. (2025). Phylogenetic analysis of *Mycobacterium caprae* highlights past and present epidemiological links at the Iberian Peninsula scale. Microbes and Infection, 27(2), 105405. <a href="https://doi.org/10.1016/j.micinf.2024.105405">https://doi.org/10.1016/j.micinf.2024.105405</a>
- [11] Boniotti, M. B., Goria, M., Loda, D., Garrone, A., Benedetto, A., Mondo, A., ... & Pacciarini, M. L. (2009). Molecular typing of *Mycobacterium bovis* strains isolated in Italy from 2000 to 2006 and evaluation of variable-number tandem repeats for geographically optimized genotyping. Journal of Clinical Microbiology, 47(3), 636-644. <a href="https://doi.org/10.1128/JCM.01192-08">https://doi.org/10.1128/JCM.01192-08</a>
- [12] Papaventsis, D., Dougas, G., Kalkouni, O., Karabela, S., & Manika, K. (2021). Occupational exposure to zoonotic tuberculosis caused by *Mycobacterium caprae*, Northern Greece, 2019. Emerging Infectious Diseases, 27(7), 1997-1999. <a href="https://doi.org/10.3201/eid2707.204399">https://doi.org/10.3201/eid2707.204399</a>
- [13] Valcheva, V., Perea, C., Savova-Lalkovska, T., Dimitrova, A., Radulski, L., Mokrousov, I., ... & Bonovska, M. (2022). *Mycobacterium bovis* and *M. caprae* in Bulgaria: Insight into transmission and phylogeography gained through whole-genome sequencing. BMC Veterinary Research, 18(1), 148. https://doi.org/10.1186/s12917-022-03249-w
- [14] Domogalla, J., Prodinger, W. M., Blum, H., Krebs, S., Gellert, S., Müller, M., ... & Büttner, M. (2013). Region of difference 4 in alpine *Mycobacterium caprae* isolates indicates three variants. Journal of Clinical Microbiology, 51(5), 1381-1388. https://doi.org/10.1128/JCM.02966-12
- [15] Bertasio, C., Carta, V., Parisio, G., Zanoni, M., Tamba, M., Mazzera, L., ... & Boniotti, M. B. (2025). *M. caprae* in northern Italy: a comprehensive analysis through wholegenome sequencing on the genetic variability in bovine herds. Veterinary Research, 56(1), 163. <a href="https://doi.org/10.1186/s13567-025-01585-x">https://doi.org/10.1186/s13567-025-01585-x</a>
- [16] Lamine-Khemiri, H., Martínez, R., García-Jiménez, W. L., Benítez-Medina, J. M., Cortés, M., Hurtado, I., ... & Hermoso-de-Mendoza, J. (2014). Genotypic characterization by spoligotyping and VNTR typing of *Mycobacterium bovis* and *Mycobacterium caprae* isolates from cattle of Tunisia. Tropical Animal Health and Production, 46(2), 305-311. <a href="https://doi.org/10.1007/s11250-013-0488-y">https://doi.org/10.1007/s11250-013-0488-y</a>
- [17] European Food Safety Authority (EFSA) and European Centre for Disease Prevention and Control (ECDC). (2024):

The European union one health 2023 zoonoses report. European Food Safety Authority Journal, 22(12), e9106. https://doi.org/10.2903/j.efsa.2024.9106

[18] Gunasingam, N. (2022). Morphology and pathological characteristics of mycobacteria. Mycobacterial Diseases, 12(S4), 1000005. <a href="https://doi.org/10.35248/2161-1068.22">https://doi.org/10.35248/2161-1068.22</a>. S4.005

[19] Riojas, M. A., McGough, K. J., Rider-Riojas, C. J., Rastogi, N., & Hazbón, M. H. (2018). Phylogenomic analysis of the species of the *Mycobacterium tuberculosis* complex demonstrates that *Mycobacterium africanum*, *Mycobacterium bovis*, *Mycobacterium caprae*, *Mycobacterium microti* and *Mycobacterium pinnipedii* are later heterotypic synonyms of *Mycobacterium tuberculosis*. International Journal of Systematic and Evolutionary Microbiology, 68(1), 324-332. <a href="https://doi.org/10.1099/ijsem.0.002507">https://doi.org/10.1099/ijsem.0.002507</a>

[20] Aranaz, A., Liébana, E., Gómez-Mampaso, E., Galán, J. C., Cousins, D., Ortega, A., ... & Domínguez, L. (1999). *Mycobacterium tuberculosis* subsp. *caprae subsp. nov.*: A taxonomic study of a new member of the *Mycobacterium tuberculosis* complex isolated from goats in Spain. International Journal of Systematic and Evolutionary Microbiology, 49(3), 1263-1273. <a href="https://doi.org/10.1099/00207713-49-3-1263">https://doi.org/10.1099/00207713-49-3-1263</a>

[21] Sneath, P. H. A (1992). International code of nomenclature of bacteria (1990 Revision). American Society for Microbiology, Washington, USA.

[22] Niemann, S., Richter, E., & Rüsch-Gerdes, S. (2002). Biochemical and genetic evidence for the transfer of *Mycobacterium tuberculosis subsp. caprae Aranaz* et al. 1999 to the species *Mycobacterium bovis* Karlson and Lessel 1970 (approved lists 1980) as *Mycobacterium bovis subsp. caprae comb. nov*. International Journal of Systematic and Evolutionary Microbiology, 52(2), 433-436. <a href="https://doi.org/10.1099/00207713-52-2-433">https://doi.org/10.1099/00207713-52-2-433</a>

[23] De Vos, P., & Truper, H. G. (2000). Judicial commission of the international committee on systematic bacteriology; IXth international (IUMS) congress of bacteriology and applied microbiology. International Journal of Systematic and Evolutionary Microbiology, 50(6), 2239-2244. <a href="https://doi.org/10.1099/00207713-50-6-2239">https://doi.org/10.1099/00207713-50-6-2239</a>

[24] Aranaz, A., Cousins, D., Mateos, A., & Domínguez, L. (2003). Elevation of *Mycobacterium tuberculosis subsp.* 

caprae Aranaz et al. 1999 to species rank as Mycobacterium caprae comb. nov., sp. nov. International Journal of Systematic and Evolutionary Microbiology, 53(6), 1785-1789. https://doi.org/10.1099/ijs.0.02532-0

[25] Rodriguez-Campos, S., Smith, N. H., Boniotti, M. B., & Aranaz, A. (2014). Overview and phylogeny of *Mycobacterium tuberculosis* complex organisms: Implications for diagnostics and legislation of bovine tuberculosis. Research in Veterinary Science, 97, S5-S19. https://doi.org/10.1016/j.rvsc.2014.02.009

[26] Karlson, A. G., & Lessel, E. F. (1970). *Mycobacterium bovis nom. nov.* International Journal of Systematic and Evolutionary Microbiology, 20(3), 273-282. <a href="https://doi.org/10.1099/00207713-20-3-273">https://doi.org/10.1099/00207713-20-3-273</a>

[27] Jagielski, T., Minias, A., van Ingen, J., Rastogi, N., Brzostek, A., Żaczek, A., & Dziadek, J. (2016). Methodological and clinical aspects of the molecular epidemiology of *Mycobacterium tuberculosis* and other mycobacteria. Clinical Microbiology Reviews, 29(2), 239-290. https://doi.org/10.1128/CMR.00055-15

[28] Pesciaroli, M., Alvarez, J., Boniotti, M. B., Cagiola, M., Di Marco, V., Marianelli, C., ... & Pasquali, P. (2014). Tuberculosis in domestic animal species. Research in Veterinary Science, 97, S78-S85. <a href="https://doi.org/10.1016/j.rvsc.2014.05.015">https://doi.org/10.1016/j.rvsc.2014.05.015</a>

[29] Reis, A. C., Albuquerque, T., Botelho, A., & Cunha, M. V. (2020). Polyclonal infection as a new scenario in *Mycobacterium caprae* epidemiology. Veterinary Microbiology, 240, 108533. <a href="https://doi.org/10.1016/j.vetmic.2019.108533">https://doi.org/10.1016/j.vetmic.2019.108533</a>

[30] Vidal, E., Grasa, M., Perálvarez, T., Martín, M., Mercader, I., & de Val, B. P. (2018). Transmission of tuberculosis caused by *Mycobacterium caprae* between dairy sheep and goats. Small Ruminant Research, 158, 22-25. <a href="https://doi.org/10.1016/j.smallrumres.2017.11.010">https://doi.org/10.1016/j.smallrumres.2017.11.010</a>

[31] Cvetnic, Z., Katalinic-Jankovic, V., Sostaric, B., Spicic, S., Obrovac, M., Marjanovic, S., ... & Vickovic, I. (2007). *Mycobacterium caprae* in cattle and humans in Croatia. The International Journal of Tuberculosis and Lung Disease, 11(6), 652-658.

[32] Pate, M., Švara, T., Gombač, M., Paller, T., ŽOlnir-Dovč, M., Emeršič, I., ... & Ocepek, M. (2006). Outbreak of tuberculosis caused by *Mycobacterium caprae* in a zoological

garden. Journal of Veterinary Medicine, Series B, 53(8), 387-392. https://doi.org/10.1111/j.1439-0450.2006.01000.x

[33] Chiari, M., Zanoni, M., Alborali, L. G., Zanardi, G., Avisani, D., Tagliabue, S., ... & Boniotti, M. B. (2014). Isolation of *Mycobacterium caprae* (Lechtal genotype) from red deer (Cervus elaphus) in Italy. Journal of wildlife Diseases, 50(2), 330-333. <a href="https://doi.org/10.7589/2013-06-135">https://doi.org/10.7589/2013-06-135</a>

[34] Amato, B., Capucchio, T. M., Biasibetti, E., Mangano, E., Boniotti, B. M., Pacciarini, L. M., ... & Presti, V. D. M. L. (2017). Pathology and genetic findings in a rare case of *Mycobacterium caprae* infection in a sow. Veterinary Microbiology, 205, 71-74. <a href="https://doi.org/10.1016/j.vetmic.2017.05.010">https://doi.org/10.1016/j.vetmic.2017.05.010</a>

[35] Gola, C., Marrero, J. D., Fingerhood, S., Pérez, M. H., & Santana, P. D. (2025). Systemic *Mycobacterium caprae* infection in a domestic cat in the United Kingdom: a case report. Animal Diseases, 5(1), 12. <a href="https://doi.org/10.1186/s44149-025-00163-0">https://doi.org/10.1186/s44149-025-00163-0</a>

[36] Schoepf, K., Prodinger, W. M., Glawischnig, W., Hofer, E., Revilla-Fernandez, S., Hofrichter, J., ... & Schmoll, F. (2012). A Two-Years' Survey on the Prevalence of Tuberculosis Caused by *Mycobacterium caprae* in Red Deer (*Cervus elaphus*) in the Tyrol, Austria. International Scholarly Research Notices, 2012(1), 245138. <a href="https://doi.org/10.5402/2012/245138">https://doi.org/10.5402/2012/245138</a>

[37] Fink, M., Schleicher, C., Gonano, M., Prodinger, W. M., Pacciarini, M., Glawischnig, W., ... & Büttner, M. (2015). Red deer as maintenance host for bovine tuberculosis, Alpine region. Emerging Infectious Diseases, 21(3), 464. https://doi.org/10.3201/eid2103.141119

[38] Steinparzer, R., Stanclova, G., Bagó, Z., Revilla-Fernández, S., Leth, C., Hofer, E., ... & Schmoll, F. (2020). Generalized tuberculosis due to *Mycobacterium caprae* in a red fox (*Vulpes vulpes*) in Austria. Journal of Wildlife Diseases, 56(4), 956-958. <a href="https://doi.org/10.7589/2019-10-249">https://doi.org/10.7589/2019-10-249</a>

[39] Orłowska, B., Krajewska-Wędzina, M., Augustynowicz-Kopeć, E., Kozińska, M., Brzezińska, S., Zabost, A., ... & Anusz, K. (2020). Epidemiological characterization of *Mycobacterium caprae* strains isolated from wildlife in the Bieszczady Mountains, on the border of Southeast

Poland. BMC Veterinary Research, 16(1), 362. https://doi.org/10.1186/s12917-020-02581-3

[40] Krajewska, M., Lipiec, M., Zabost, A., Augustynowicz-Kopeć, E., & Szulowski, K. (2014). Bovine tuberculosis in a wild boar (*Sus scrofa*) in Poland. Journal of wildlife Diseases, 50(4), 1001-1002. <a href="https://doi.org/10.7589/2013-07-187">https://doi.org/10.7589/2013-07-187</a>

[41] Yoshida, S., Suga, S., Ishikawa, S., Mukai, Y., Tsuyuguchi, K., Inoue, Y., ... & Wada, T. (2018). *Mycobacterium caprae* infection in captive Borneo elephant, Japan. Emerging Infectious Diseases, 24(10), 1937. https://doi.org/10.3201/eid2410.180018

[42] Roy, Á., Gómez-Barroso, D., Cruz-Ferro, E., Fernández, A., Martínez-Pino, I., del Henar Marcos, M., ... & Herrador, Z. (2025). Spatiotemporal distribution and clinical characteristics of Zoonotic Tuberculosis, Spain, 2018–2022. Emerging Infectious Diseases, 31(7), 1344. <a href="https://doi.org/10.3201/eid3107.250031">https://doi.org/10.3201/eid3107.250031</a>

[43] Kozińska, M., Krajewska-Wędzina, M., & Augustynowicz-Kopeć, E. (2020). Mycobacterium caprae-the first case of the human infection in Poland. Annals of Agricultural and Environmental Medicine, 27(1), 151-153. https://doi.org/10.26444/aaem/108442

[44] Prodinger, W. M., Indra, A., Koksalan, O. K., Kilicaslan, Z., & Richter, E. (2014). *Mycobacterium caprae* infection in humans. Expert Review of Anti-Infective Therapy, 12(12), 1501-1513. <a href="https://doi.org/10.1586/14787210.2014.974560">https://doi.org/10.1586/14787210.2014.974560</a>

[45] Bayraktar, B., Bulut, E., Barış, A. B., Toksoy, B., Dalgıc, N., Celikkan, C., & Sevgi, D. (2011). Species distribution of the *Mycobacterium tuberculosis* complex in clinical isolates from 2007 to 2010 in Turkey: a prospective study. Journal of Clinical Microbiology, 49(11), 3837-3841. <a href="https://doi.org/10.1128/JCM.01172-11">https://doi.org/10.1128/JCM.01172-11</a>

[46] Rodríguez, E., Sánchez, L. P., Pérez, S., Herrera, L., Jiménez, M. S., Samper, S., & Iglesias, M. (2009). Human tuberculosis due to *Mycobacterium bovis* and *M. caprae* in Spain, 2004–2007. The International Journal of Tuberculosis and Lung Disease, 13(12), 1536-1541.

[47] Shrestha, A., Picoy, J., Torres, A., Moore, D. A., Gilman, R. H., Coronel, J. and Grandjean, L. (2021): A case report of transmission and disease caused by *Mycobacterium caprae* and *Mycobacterium bovis* in Lima, Peru. BMC Infectious

- Diseases, 21(1), 12651265-. <a href="https://doi.org/10.1186/s12879-021-06944-5">https://doi.org/10.1186/s12879-021-06944-5</a>
- [48] Damene, H., Tahir, D., Diels, M., Berber, A., Sahraoui, N., & Rigouts, L. (2020). Broad diversity of *Mycobacterium tuberculosis* complex strains isolated from humans and cattle in Northern Algeria suggests a zoonotic transmission cycle. PLoS Neglected Tropical Diseases, 14(11), e0008894. https://doi.org/10.1371/journal.pntd.0008894
- [49] Martínez-Lirola, M., Herranz, M., Serrano, S. B., Rodríguez-Grande, C., Inarra, E. D., Garrido-Cárdenas, J. A., ... & de Viedma, D. G. (2023). A One Health approach revealed the long-term role of *Mycobacterium caprae* as the hidden cause of human tuberculosis in a region of Spain, 2003 to 2022. Eurosurveillance, 28(12), 2200852. <a href="https://doi.org/10.2807/1560-7917.ES.2023.28.12.2200852">https://doi.org/10.2807/1560-7917.ES.2023.28.12.2200852</a>
- [50] Pavlik, I., Bures, F., Janovsky, P., Pecinka, P., Bartos, M., Dvorska, L., ... & Van Soolingen, D. (2002). The last outbreak of bovine tuberculosis in cattle in the CzechRepublic in 1995 was caused by *Mycobacterium bovis* subspecies caprae. Veterinární Medicína, 47(9), 251. <a href="https://doi.org/10.17221/5832-VETMED">https://doi.org/10.17221/5832-VETMED</a>
- [51] Renwick, A. R., White, P. C. L., & Bengis, R. G. (2007). Bovine tuberculosis in southern African wildlife: a multispecies host–pathogen system. Epidemiology & Infection, 135(4), 529-540. <a href="https://doi.org/10.1017/S0950268806007205">https://doi.org/10.1017/S0950268806007205</a>
- [52] Wobeser, G. (2009). Bovine tuberculosis in Canadian wildlife: an updated history. The Canadian Veterinary Journal, 50(11), 1169.
- [53] Dorn-In, S., Körner, T., Büttner, M., Hafner-Marx, A., Müller, M., Heurich, M., ... & Schwaiger, K. (2020). Shedding of *Mycobacterium caprae* by wild red deer (*Cervus elaphus*) in the Bavarian alpine regions, Germany. Transboundary and Emerging Diseases, 67(1), 308-317. <a href="https://doi.org/10.1111/tbed.13353">https://doi.org/10.1111/tbed.13353</a>
- [54] Palmer, M. V., Waters, W. R., & Whipple, D. L. (2004). Shared feed as a means of deer-to-deer transmission of *Mycobacterium bovis*. Journal of Wildlife Diseases, 40(1), 87-91. https://doi.org/10.7589/0090-3558-40.1.87
- [55] Hruska, K., & Kaevska, M. (2012). Mycobacteria in water, soil, plants and air: a review. Veterinarni Medicina, 57(12), 623-679. <a href="https://doi.org/10.17221/6558-VETMED">https://doi.org/10.17221/6558-VETMED</a>

- [56] Guimaraes, A. M., & Zimpel, C. K. (2020). Mycobacterium bovis: from genotyping to genome sequencing. Microorganisms, 8(5), 667. <a href="https://doi.org/10.3390/microorganisms8050667">https://doi.org/10.3390/microorganisms8050667</a>
- [57] de La Fuente, J., Díez-Delgado, I., Contreras, M., Vicente, J., Cabezas-Cruz, A., Tobes, R., ... & Gortazar, C. (2015). Comparative genomics of field isolates of *Mycobacterium bovis* and *M. caprae* provides evidence for possible correlates with bacterial viability and virulence. PLOS Neglected Tropical Diseases, 9(11), e0004232. <a href="https://doi.org/10.1371/journal.pntd.0004232">https://doi.org/10.1371/journal.pntd.0004232</a>
- [58] Forrellad, M. A., Klepp, L. I., Gioffré, A., Sabio y Garcia, J., Morbidoni, H. R., Santangelo, M. D. L. P., ... & Bigi, F. (2013). Virulence factors of the *Mycobacterium tuberculosis* complex. Virulence, 4(1), 3-66. <a href="https://doi.org/10.4161/viru.22329">https://doi.org/10.4161/viru.22329</a>
- [59] Simeone, R., Bottai, D., Frigui, W., Majlessi, L., & Brosch, R. (2015). ESX/type VII secretion systems of mycobacteria: Insights into evolution, pathogenicity and protection. Tuberculosis, 95, S150-S154. <a href="https://doi.org/10.1016/j.tube.2015.02.019">https://doi.org/10.1016/j.tube.2015.02.019</a>
- [60] Ghazaei, C. (2018). Mycobacterium tuberculosis and lipids: Insights into molecular mechanisms from persistence to virulence. Journal of Research in Medical Sciences, 23(1), 63. <a href="https://doi.org/10.4103/jrms.JRMS">https://doi.org/10.4103/jrms.JRMS</a> 904 17
- [61] Domogalla, J., Prodinger, W. M., Blum, H., Krebs, S., Gellert, S., Müller, M., ... & Büttner, M. (2013). Region of difference 4 in alpine *Mycobacterium caprae* isolates indicates three variants. Journal of Clinical Microbiology, 51(5), 1381-1388. https://doi.org/10.1128/JCM.02966-12
- [62] Ernst, J. D. (2017). Antigenic variation and immune escape in the MTBC. Strain Variation in the Mycobacterium Tuberculosis Complex: Its Role in Biology, Epidemiology and Control, 171-190. <a href="https://doi.org/10.1007/978-3-319-64371-79">https://doi.org/10.1007/978-3-319-64371-79</a>
- [63] da Silva Rabello, M. C., Santos, F. C. F., de Albuquerque Montenegro, R., Guedes, G. D. M. R., Montenegro, L. M. L., & Schindler, H. C. (2017). TUBERCULOSIS: Epidemiological, Molecular, Immunological and Clinical Characteristics. In Tropical Diseases: An Overview of Major Diseases Occurring in the Americas (pp. 373-400). Bentham Science Publishers. <a href="https://doi.org/10.2174/9781681">https://doi.org/10.2174/9781681</a>

- [64] Hansen, N., Seiler, C., Rumpf, J., Kraft, P., Dlaske, H., Abele-Horn, M., & Muellges, W. (2012). Human tuberculous meningitis caused by *Mycobacterium caprae*. Case Reports in Neurology, 4(1), 54-60. <a href="https://doi.org/10.1159/000337299">https://doi.org/10.1159/000337299</a> [65] Kılınc, F., Çetin, F. T., Tapac, N., Gundeslioglu, O. O., & Alabaz, D. (2025). Intracranial tuberculoma developing during the treatment of a case with tuberculous meningitis caused by
- Alabaz, D. (2025). Intracranial tuberculoma developing during the treatment of a case with tuberculous meningitis caused by the zoonotic mycobacterium caprae. Klinische Pädiatrie, 237(05), 302-304. <a href="https://doi.org/10.1055/a-2244-7061">https://doi.org/10.1055/a-2244-7061</a>
- [66] Parsons, L. M., Somoskövi, Á., Gutierrez, C., Lee, E., Paramasivan, C. N., Abimiku, A. L., ... & Nkengasong, J. (2011). Laboratory diagnosis of tuberculosis in resource-poor countries: challenges and opportunities. Clinical Microbiology Reviews, 24(2), 314-350. <a href="https://doi.org/10.1128/CMR.00059-10">https://doi.org/10.1128/CMR.00059-10</a>
- [67] Rodriguez, S., Bezos, J., Romero, B., de Juan, L., Alvarez, J., Castellanos, E., ... & on Surveillance, T. S. N. (2011). *Mycobacterium caprae* infection in livestock and wildlife, Spain. Emerging Infectious Diseases, 17(3), 532. <a href="https://doi.org/10.3201/eid1703.100618">https://doi.org/10.3201/eid1703.100618</a>
- [68] Perez de Val, B., López-Soria, S., Nofrarías, M., Martín, M., Vordermeier, H. M., Villarreal-Ramos, B., ... & Domingo, M. (2011). Experimental model of tuberculosis in the domestic goat after endobronchial infection with *Mycobacterium caprae*. Clinical and Vaccine Immunology, 18(11), 1872-1881. https://doi.org/10.1128/CVI.05323-11
- [69] Ozturk-Gurgen, H., Rieseberg, B., Leipig-Rudolph, M., Straubinger, R. K., & Hermanns, W. (2020). Morphology of naturally-occurring tuberculosis in cattle caused by *Mycobacterium caprae*. Journal of Comparative Pathology, 174, 120-139. <a href="https://doi.org/10.1016/j.jcpa.2019.11.010">https://doi.org/10.1016/j.jcpa.2019.11.010</a>
- [70] Nigsch, A., Glawischnig, W., Bagó, Z., & Greber, N. (2019). *Mycobacterium caprae* infection of red deer in Western Austria–optimized use of pathology data to infer infection dynamics. Frontiers in Veterinary Science, 5, 350. <a href="https://doi.org/10.3389/fvets.2018.00350">https://doi.org/10.3389/fvets.2018.00350</a>
- [71] Bayraktar, B., Togay, A., Gencer, H., Kockaya, T., Dalgic, N., & Bulut, E. (2011). *Mycobacterium caprae* causing lymphadenitis in a child. The Pediatric Infectious Disease Journal, 30(11), 1012-1013. <a href="https://doi.org/10.1097/INF.0b013e3182276f7c">https://doi.org/10.1097/INF.0b013e3182276f7c</a>

- [72] Lekko, Y. M., Ooi, P. T., Omar, S., Mazlan, M., Ramanoon, S. Z., Jasni, S., ... & Che-Amat, A. (2020). Mycobacterium tuberculosis complex in wildlife: Review of current applications of antemortem and postmortem diagnosis. Veterinary World, 13(9), 1822. <a href="https://doi.org/10.14202/vetworld.2020.1822-1836">https://doi.org/10.14202/vetworld.2020.1822-1836</a>
- [73] Schiller, I., RayWaters, W., Vordermeier, H. M., Jemmi, T., Welsh, M., Keck, N., ... & Oesch, B. (2011). Bovine tuberculosis in Europe from the perspective of an officially tuberculosis free country: trade, surveillance and diagnostics. Veterinary Microbiology, 151(1-2), 153-159. https://doi.org/10.1016/j.vetmic.2011.02.039
- [74] Kedir, E., Mamo, G., Legesse, K., & Tassew, A. (2018). Review on advanced diagnostic techniques for *Mycobacterium species* and its significance to control tuberculosis. Journal of Bacteriology & Mycology. Open Access, 6(3), 168-177. <a href="https://doi.org/10.15406/jbmoa.2018.06.00198">https://doi.org/10.15406/jbmoa.2018.06.00198</a>
- [75] Barletta, R. G., & Steffen, D. J. (2022). Mycobacteria. Veterinary Microbiology, 345-359. https://doi.org/10.1002/9781119650836.ch36
- [76] World Organisation for Animal Health. (2022). *Mammalian tuberculosis (Infection with Mycobacterium tuberculosis Complex)* (Chapter 3.1.13). WOAH Terrestrial Manual. <a href="https://www.woah.org/fileadmin/Home/eng/Health\_standards/tahm/202406\_Chapter\_3.01.13\_MAMMALIAN%">https://www.woah.org/fileadmin/Home/eng/Health\_standards/tahm/202406\_Chapter\_3.01.13\_MAMMALIAN%</a>
  20TB.pdf
- [77] Szacawa, E., Radulski, Ł., Weiner, M., Szulowski, K., & Krajewska-Wędzina, M. (2025). *Mycobacterium tuberculosis* complex infections in animals: A comprehensive review of species distribution and laboratory diagnostic methods. Pathogens, 14(10), 1004. <a href="https://doi.org/10.3390/pathogens14101004">https://doi.org/10.3390/pathogens14101004</a>
- [78] Niemann, S., Richter, E., & Rüsch-Gerdes, S. (2000). Differentiation among members of the Mycobacterium tuberculosis complex by molecular and biochemical features: evidence for two pyrazinamide-susceptible subtypes of *M. bovis*. Journal of Clinical Microbiology, 38(1), 152-157. https://doi.org/10.1128/JCM.38.1.152-157.2000
- [79] Niemann, S., Harmsen, D., Rüsch-Gerdes, S., & Richter, E. (2000). Differentiation of clinical *Mycobacterium tuberculosis* complex isolates by *gyrB* DNA sequence polymorphism analysis. Journal of Clinical

Microbiology, 38(9), 3231-3234. <a href="https://doi.org/10.1128/JCM.38.9.3231-3234.2000">https://doi.org/10.1128/JCM.38.9.3231-3234.2000</a>

[80] Kasai, H., Ezaki, T., & Harayama, S. (2000). Differentiation of phylogenetically related slowly growing mycobacteria by their *gyrB* sequences. Journal of Clinical Microbiology, 38(1), 301-308. <a href="https://doi.org/10.1128/JCM.38.1.301-308.2000">https://doi.org/10.1128/JCM.38.1.301-308.2000</a>

[81] Lorente-Leal, V., Gomez-Buendia, A., Gutiérrez-Tobaruela, A., de Juan, L., Bezos, J., & Romero, B. (2024). Shaken, not stirred: magnetic bead DNA extraction as a rapid and effective method for the scaling up of bovine tuberculosis diagnosis. BMC Veterinary Research, 20(1), 568. https://doi.org/10.1186/s12917-024-04427-8

[82] Chaudhari, K. V., Toi, P. C., and Joseph, N. M. (2021). Evaluation of real time polymerase chain reaction targeting *mpb64* gene for diagnosis of extrapulmonary tuberculosis. Indian Journal of Tuberculosis. <a href="https://doi.org/10.1016/j.ijtb.2020.09.009">https://doi.org/10.1016/j.ijtb.2020.09.009</a>

[83] Reddington, K., O'Grady, J., Dorai-Raj, S., Niemann, S., van Soolingen, D., and Barry, T. (2011): A novel multiplex real-time PCR for the identification of mycobacteria associated with zoonotic tuberculosis. PloS One, 6(8): e23481. https://doi.org/10.1371/journal.pone.0023481

[84] Kamerbeek, J., Schouls, L. E. O., Kolk, A., Van Agterveld, M., Van Soolingen, D., Kuijper, S., ... & van Embden, J. (1997). Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. Journal of Clinical Microbiology, 35(4), 907-914. https://doi.org/10.1128/jcm.35.4.907-914.1997

[85] Liébana, E., Aranaz, A., Dominguez, L., Mateos, A., González-Llamazares, O., Rodriguez-Ferri, E. F., ... & Cousins, D. (1997). The insertion element *IS6110* is a useful tool for DNA fingerprinting of *Mycobacterium bovis* isolates from cattle and goats in Spain. Veterinary Microbiology, 54(3-4), 223-233. <a href="https://doi.org/10.1016/S0378-1135(96)01282-5">https://doi.org/10.1016/S0378-1135(96)01282-5</a>

[86] Aranaz, A., Liébana, E., Mateos, A., Domínguez, L., & Cousins, D. (1998). Restriction fragment length polymorphism and spacer oligonucleotide typing: a comparative analysis of fingerprinting strategies for *Mycobacterium bovis*. Veterinary Microbiology, 61(4), 311-324. https://doi.org/10.1016/S0378-1135(98)00192-8

[87] Brosch, R., Gordon, S. V., Marmiesse, M., Brodin, P., Buchrieser, C., Eiglmeier, K., ... & Cole, S. T. (2002). A new evolutionary scenario for the *Mycobacterium tuberculosis* complex. Proceedings of The National Academy of Sciences, 99(6), 3684-3689. <a href="https://doi.org/10.1073/pnas.052548299">https://doi.org/10.1073/pnas.052548299</a>

[88] Mostowy, S., Cousins, D., Brinkman, J., Aranaz, A., & Behr, M. A. (2002). Genomic deletions suggest phylogeny for the *Mycobacterium tuberculosis* complex. The Journal of Infectious Diseases, 186(1), 74-80. <a href="https://doi.org/10.1086/341068">https://doi.org/10.1086/341068</a>

[89] Duarte, E. L., Domingos, M., Amado, A., Cunha, M. V., & Botelho, A. (2010). MIRU-VNTR typing adds discriminatory value to groups of *Mycobacterium bovis* and *Mycobacterium caprae* strains defined by spoligotyping. Veterinary Microbiology, 143(2-4), 299-306. <a href="https://doi.org/10.1016/j.vetmic.2009.11.027">https://doi.org/10.1016/j.vetmic.2009.11.027</a>

[90] Macedo Couto, R., Ranzani, O. T., & Waldman, E. A. (2019). Zoonotic tuberculosis in humans: Control, surveillance, and the one health approach. Epidemiologic Reviews, 41(1), 130-144. <a href="https://doi.org/10.1093/epirev/mxz002">https://doi.org/10.1093/epirev/mxz002</a>

[91] Islam, M. R., Sharma, M. K., KhunKhun, R., Shandro, C., Sekirov, I., Tyrrell, G. J., & Soualhine, H. (2023). Whole genome sequencing-based identification of human tuberculosis caused by animal-lineage *Mycobacterium orygis*. Journal of Clinical Microbiology, 61(11), e00260-23. <a href="https://doi.org/10.1128/jcm.00260-23">https://doi.org/10.1128/jcm.00260-23</a>

[92] Fine, A.E., Bolin, C.A., Gardiner, J.C., and Kaneene, J.B. (2011). A Study of the Persistence of *Mycobacterium bovis* in the Environment under Natural Weather Conditions in Michigan, USA. Veterinary Medicine International, 2011, 765430. https://doi.org/10.4061/2011/765430

[93] Zhang, H., Liu, M., Fan, W., Sun, S., & Fan, X. (2022). The impact of *Mycobacterium tuberculosis* complex in the environment on one health approach. Frontiers in Public Health, 10, 994745. <a href="https://doi.org/10.3389/fpubh.2022.994745">https://doi.org/10.3389/fpubh.2022.994745</a>

[94] Martinez, L., Verma, R., Croda, J., Horsburgh Jr, C. R., Walter, K. S., Degner, N., ... & Andrews, J. R. (2019). Detection, survival and infectious potential of *Mycobacterium tuberculosis* in the environment: a review of the evidence and

epidemiological implications. European Respiratory Journal, 53(6). <a href="https://doi.org/10.1183/13993003.02302-2018">https://doi.org/10.1183/13993003.02302-2018</a>

[95] zu Bentrup, K. H., & Russell, D. G. (2001). Mycobacterial persistence: adaptation to a changing environment. Trends in Microbiology, 9(12), 597-605. <a href="https://doi.org/10.1016/S0966-842X(01)02238-7">https://doi.org/10.1016/S0966-842X(01)02238-7</a>

[96] Barasona, J. A., Vicente, J., Díez-Delgado, I., Aznar, J., Gortázar, C., & Torres, M. J. (2017). Environmental presence of *Mycobacterium tuberculosis* complex in aggregation points at the wildlife/livestock interface. Transboundary and Emerging Diseases, 64(4), 1148-1158. <a href="https://doi.org/10.1111/tbed.12480">https://doi.org/10.1111/tbed.12480</a>

[97] Santos, N., Santos, C., Valente, T., Gortázar, C., Almeida, V., & Correia-Neves, M. (2015). Widespread environmental contamination with *Mycobacterium tuberculosis* complex revealed by a molecular detection protocol. PLoS One, 10(11), e0142079. https://doi.org/10.1371/journal.pone.0142079

[98] Gormley, E., & Collins, J. D. (2000). The development of wildlife control strategies for eradication of tuberculosis in cattle in Ireland. Tubercle and Lung Disease, 80(4-5), 229-236. https://doi.org/10.1054/tuld.2000.0250

[99] Vidal, E., Arrieta-Villegas, C., Grasa, M., Mercader, I., Domingo, M., & Pérez de Val, B. (2017). Field evaluation of the efficacy of *Mycobacterium bovis* BCG vaccine against tuberculosis in goats. BMC Veterinary Research, 13(1), 252. <a href="https://doi.org/10.1186/s12917-017-1182-5">https://doi.org/10.1186/s12917-017-1182-5</a>

[100] Carter, S. P., Chambers, M. A., Rushton, S. P., Shirley, M. D., Schuchert, P., Pietravalle, S., ... & McDonald, R. A. (2012). BCG vaccination reduces risk of tuberculosis infection in vaccinated badgers and unvaccinated badger cubs. PloS One, 7(12), e49833. https://doi.org/10.1371/journal.pone. 0049833

[101] Wedlock, D. N., Skinner, M. A., de Lisle, G. W., & Buddle, B. M. (2002). Control of *Mycobacterium bovis* infections and the risk to human populations. Microbes and Infection, 4(4), 471-480. <a href="https://doi.org/10.1016/S1286-4579(02)01562-9">https://doi.org/10.1016/S1286-4579(02)01562-9</a>

[102] Sebastianski, M., Bridger, N. A., Featherstone, R. M., & Robinson, J. L. (2022). Disease outbreaks linked to pasteurized and unpasteurized dairy products in Canada and the United States: a systematic review. Canadian Journal of Public Health, 113(4), 569-578. <a href="https://doi.org/10.17269/s41997-022-00614-y">https://doi.org/10.17269/s41997-022-00614-y</a>

[103] Allen, A. R., Ford, T., & Skuce, R. A. (2021). Does *Mycobacterium tuberculosis var. bovis* survival in the environment confound bovine tuberculosis control and eradication? A literature review. Veterinary Medicine International, 2021(1), 8812898. <a href="https://doi.org/10.1155/2021/8812898">https://doi.org/10.1155/2021/8812898</a>

[104] Riopel, N. D., Long, R., Heffernan, C., Tyrrell, G. J., Shandro, C., Li, V., ... & Cooper, R. (2024). Characterization of *Mycobacterium orygis*, *Mycobacterium bovis*, and *Mycobacterium caprae* infections in humans in Western Canada. The Journal of Infectious Diseases, 230(4), e789-e797. https://doi.org/10.1093/infdis/jiae124

[105] Chakaya, J., Khan, M., Ntoumi, F., Aklillu, E., Fatima, R., Mwaba, P., ... & Zumla, A. (2021). Global Tuberculosis Report 2020–Reflections on the Global TB burden, treatment and prevention efforts. International Journal of Infectious Diseases, 113, S7-S12. <a href="https://doi.org/10.1016/j.ijid.2021.02.107">https://doi.org/10.1016/j.ijid.2021.02.107</a>

[106] Pawlowski, A., Jansson, M., Sköld, M., Rottenberg, M. E., & Källenius, G. (2012). Tuberculosis and HIV co-infection. PLoS Pathogens, 8(2), e1002464. <a href="https://doi.org/10.1371/journal.ppat.1002464">https://doi.org/10.1371/journal.ppat.1002464</a>

[107]Pinto, M., & Macedo, R. (2025). Whole-genome sequencing-based surveillance system for *Mycobacterium tuberculosis* in Portugal. Tuberculosis, 102691. <a href="https://doi.org/10.1016/j.tube.2025.102691">https://doi.org/10.1016/j.tube.2025.102691</a>

[108]Olea-Popelka, F., & Fujiwara, P. I. (2018). Building a multi-institutional and interdisciplinary team to develop a zoonotic tuberculosis roadmap. Frontiers in Public Health, 6, 167. https://doi.org/10.3389/fpubh.2018.00167

[109] Katale, B. Z., Mbugi, E. V., Keyyu, J. D., Fyumagwa, R. D., Rweyemamu, M. M., Van Helden, P. D., ... & Matee, M. I. (2019). One Health approach in the prevention and control of mycobacterial infections in Tanzania: lessons learnt and future perspectives. One Health Outlook, 1(1), 2. <a href="https://doi.org/10.1186/s42522-019-0002-1">https://doi.org/10.1186/s42522-019-0002-1</a>